Halozyme Therapeutics (HALO) FY2013 results: revenue $55 million, up 29.5% on the year
Halozyme Therapeutics, Inc. (HALO) reported revenue of $55 million for fiscal 2013, the year ended 31 December 2013, up 29.5% on the year before. Net income was -$83 million, and diluted earnings per share $-0.74. The figures are the company's own, from the 10-K it filed with the SEC on 28 February 2014.
Revenue
$55 million
+29.5% on the year
FY2009FY2013
Operating margin
-146.8%
-126.7% a year earlier
FY2009FY2013
Net income
-$83 million
FY2009FY2013
Diluted EPS
-$0.74
FY2009FY2013
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2013
FY2012
FY2011
On the year
Last 8 years
Revenue
54.8
42.3
56.1
+29.5%
Cost of revenue
6.2
1.1
0.3
+470.7%
Gross profit
48.6
41.2
55.8
+17.8%
Gross margin
88.6%
97.4%
99.5%
Research and development
96.6
70.0
57.6
+38.0%
Selling, general and administrative
32.3
24.8
18.1
+30.4%
Operating income
-80.4
-53.6
-19.8
Operating margin
-146.8%
-126.7%
-35.4%
Interest expense
3.3
0.0
0.0
Net income
-83.5
-53.6
-19.8
Net margin
-152.3%
-126.5%
-35.2%
Diluted EPS
-$0.74
-$0.48
-$0.19
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2013
FY2012
FY2011
On the year
Last 8 years
Operating cash flow
-49.3
-64.3
-34.4
Capital expenditure
2.3
1.4
0.8
+62.6%
Free cash flow
-51.6
-65.7
-35.2
Free cash flow margin
-94.2%
-155.3%
-62.7%
Cash from investing
-47.9
-1.4
-0.8
Cash from financing
25.1
113
4.7
-77.8%
Depreciation and amortisation
1.2
1.1
1.1
+13.7%
Share-based compensation
9.5
8.3
5.6
+14.2%
Shares outstanding at period end
115m
113m
104m
+1.6%
Balance sheet
$ million
FY2013
FY2012
FY2011
On the year
Last 8 years
Shareholders' equity
-20.0
48.9
10.9
Debt
49.8
29.7
0.0
+67.8%
Other liabilities
72.0
56.2
54.9
+28.1%
Total liabilities and equity
102
135
65.8
-24.4%
Fixed assets
3.4
3.7
1.8
-7.5%
Investments
44.1
0.0
n/a
Cash and equivalents
27.4
99.5
52.4
-72.5%
Receivables
9.1
15.7
2.3
-42.1%
Inventory
6.2
2.7
0.6
+131.0%
Other assets
11.6
13.2
8.8
-11.8%
Total assets
102
135
65.8
-24.4%
10-K for the year ended 31 December 2013, filed 28 February 2014: the filing.